No Data
No Data
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Adds CN¥691m in Market Cap and Insiders Have a 35% Stake in That Gain
We Think That There Are Some Issues For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) Beyond Its Promising Earnings
Positive Sentiment Still Eludes Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Following 27% Share Price Slump
Baicheng Pharmaceuticals (301096.SZ): currently has no products related to smallpox vaccines.
Baicheng Medicine (301096.SZ) stated on the investor interaction platform on August 19 that Type 2 modified new drug 2022HY052, in which the company jointly invested with Peking Yuantongda Medicine Technology Co., Ltd., will confirm its revenue based on the project's research and development progress. Currently, the corresponding revenue for the completion of clinical trials of the project has not been confirmed. The company currently has no products related to smallpox vaccines.
From January to June 2024, the company's new order amount (including tax) is 0.711 billion yuan, a year-on-year increase of 13.38%.
On August 19th, Gelunhui reported that Baicheng Pharmaceuticals (301096.SZ) stated on its investor interaction platform that the company has nearly 300 ongoing self-developed projects that have not yet been converted as of June 2024. 196 have completed the pilot stage, 40 have completed the scale-up stage, and 30 are in the verification production stage. The indications cover a variety of disease areas, including respiratory, digestive, infectious, tumor, mental and neurological, cardiovascular, and so on. From January to June 2024, the company's new order amount was 711.2076 million yuan (including tax), a year-on-year increase of 13.38%; the company also provides entrusted research and development services, as well as technology transfer and intellectual property rights services.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
No Data
No Data